SCHEDULE 13D/A: RTW Investments Boosts Stake in Allurion Technologies with $2.5 Million PIPE Financing and Future Option

RTW Investments, LP and Roderick Wong, M.D. have increased their beneficial ownership in Allurion Technologies, Inc. to 29.6% through a $2.5 million private placement and hold an option for an additional $10 million investment.

Summary

• RTW Investments, LP and Roderick Wong, M.D. (the "Reporting Persons") have increased their beneficial ownership in Allurion Technologies, Inc. to 1,050,060 shares, representing 29.6% of the common stock.
• This increase is primarily due to the acquisition of 841,751 shares through a Private Investment in Public Equity (PIPE) financing.
• The PIPE financing, which closed on January 16, 2025, involved a purchase price of $2.97 per share, totaling approximately $2.5 million.
• The funds for this acquisition came from the working capital of the RTW Funds.
• Following this transaction, the total outstanding shares of Allurion Technologies are approximately 3,553,014.
• The Subscription Agreement also grants RTW Funds an option to purchase up to an additional $10 million of shares in one or more private placements over the next twelve months, subject to a definitive agreement and NYSE minimum price rules.
• RTW Funds were also granted registration rights for the newly purchased shares.

Sentiment

Score: 8

Explanation: The document details a significant capital infusion and increased strategic investment from a major institutional investor, along with an option for substantial future funding. This indicates strong investor confidence and provides financial stability and growth potential for the company.

Positives

• Significant capital infusion of $2.5 million into Allurion Technologies through a PIPE financing.
• Potential for an additional $10 million in future private placements from RTW Funds, indicating strong investor confidence and a potential long-term partnership.
• RTW Funds were granted registration rights, which can facilitate future liquidity for their investment.
• Increased beneficial ownership by a major institutional investor (RTW Investments) to 29.6% signals strong conviction in the company's prospects.

Risks

• Beneficial ownership conversion limitations on Notes held by RTW Funds, preventing conversion if it results in ownership exceeding 9.99% of the Issuer's shares.
• Warrant blockers on Public Warrants and Private Warrants held by RTW Funds, currently set at 4.99% and adjustable to 9.99% with 61 days' notice, which could limit immediate full exercise.
• The option for an additional $10 million investment is subject to mutual agreement and a definitive written agreement, meaning it is not guaranteed.

Future Outlook

The document indicates a potential for significant future investment, with RTW Funds holding an option to purchase up to an additional $10 million of Allurion Technologies' shares in one or more private placements over the next twelve months. This future investment would be subject to mutual agreement and a definitive written agreement, with the per-share price based on the NYSE's 'minimum price' rules.

Industry Context

This filing reflects a strategic investment by a specialized healthcare investor, RTW Investments, into Allurion Technologies, a company operating in the medical device and healthcare technology sector. Such private placements are common mechanisms for growth-stage companies to raise capital from institutional investors, particularly in sectors requiring significant R&D and market development. The substantial increase in RTW's stake suggests a strong belief in Allurion's long-term potential within the competitive healthcare landscape.

Stakeholder Impact

• Shareholders: Positive impact due to capital infusion and increased institutional confidence, potentially offsetting dilution from the PIPE.
• Company Operations: Provides working capital for ongoing operations and strategic initiatives.

Next Steps

• Potential future private placements of up to an additional $10 million in shares to RTW Funds within the next twelve months, subject to mutual agreement and a definitive written agreement.

Key Dates

Keywords

Allurion Technologies, RTW Investments, PIPE Financing, Private Placement, Common Stock, Beneficial Ownership, SEC Filing, Schedule 13D, Capital Raise, Investment, Healthcare Technology, Medical Devices